#NASDAQ DRTS
-

Alpha Tau REGAIN Trial Shows 83.3% Complete Response in Glioblastoma
Alpha Tau Medical reported interim REGAIN trial data showing five complete responses among six evaluable recurrent glioblastoma patients. The update…